title: Economic Comparison of Empirical Versus Diagonstic-Driven Strategies for Immunocompromised Patients with Suspected Fungal Infection Results from a Chinese Payer Perspective.
authors.affiliation: Pharmerit International, Bethesda, MD, USA.
authors.forename: L
authors.initials: L
authors.lastname: Qin
authors.affiliation: Pfizer Investment Co. Ltd., Beijing, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Shanghai Rui Jin Hospital, Shanghai, China.
authors.forename: W
authors.initials: W
authors.lastname: Zhao
authors.affiliation: China Pharmaceutical University, Nanjing, China.
authors.forename: N
authors.initials: N
authors.lastname: Mao
authors.affiliation: Pfizer Inc., Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Charbonneau
authors.affiliation: Pharmerit International, Bethesda, MD, USA.
authors.forename: X
authors.initials: X
authors.lastname: Gao